SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office

CALGARY, March 13, 2008 /PRNewswire-FirstCall via COMTEX/ -- SemBioSys Genetics Inc. (CA:SBS) , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has been granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The patent has been issued to SemBioSys, which has exclusively licensed commercial rights associated with the patent to Botaneco Specialty Ingredients Inc. (Botaneco), its wholly owned subsidiary. The claims of European Patent EP0986309(B1) are broadly directed to the production of emulsions comprising oleosomes extracted from any living cell, including plants such as safflower, and the use of these emulsions in a wide range of commercial applications including food ingredient, personal care and over-the-counter as well as pharmaceutical applications.

"This patent demonstrates our commitment to diligently protect our proprietary oleosome technology. It provides broad coverage for the production of personal care, topical OTC and pharmaceutical, food and other products based on emulsions comprised of oleosomes in the European market," said Andrew Baum, President and CEO of SemBioSys. "The issuance of this patent further validates our leadership in the use of oilbodies in personal care and other topical applications. We plan to launch Hydresia(TM), Botaneco's first oleosome based ingredient, in Europe this spring after a successful launch in the U.S. and Canada last year."

Counterparts to the European patent EP0986309(B1) have issued in many jurisdictions worldwide including the United States, Canada, Australia, Japan, China, India and Mexico.

In September of 2007, Botaneco commissioned its new 10,000 square foot, state-of-the-art commercial manufacturing facility for the production of its all natural oleosome base emulsion for the personal care and cosmetic markets. Botaneco recently announced that its first international brand customer, Burt's Bees, launched three personal care products in the U.S. using Botaneco's Hydresia(TM) ingredient.

About SemBioSys Genetics Inc. (
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and agricultural biotechnology markets.
About Botaneco (

From development through delivery, Botaneco manufactures and markets a branded line of ingredients that harness the naturally occurring benefits of protein protected seed oils. Botaneco provides performance, innovation and choice in creating natural, renewable and versatile delivery systems and ingredients used in the development of cosmetics, personal care and prescription topical/dermatology products beneficial to humans and the environment. Botaneco is a wholly-owned subsidiary of SemBioSys Genetics Inc.

About Hydresia(TM) (
Hydresia(TM) is a base emulsion naturally derived from safflower seed oilbodies, or oleosomes, which can replace such traditional emulsifiers as petrolatum and animal byproducts in health and beauty products. Oleosomes serve as natural storehouses for the emollient oils, antioxidants and natural moisture barriers that help keep skin soft, supple and young looking. SemBioSys has developed a gentle and natural proprietary process to isolate oleosomes from the seed fully intact to provide lasting protection to the skin.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.